If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

PDMR Shareholding

15 Aug 2019 16:59

RNS Number : 2441J
Mereo BioPharma Group plc
15 August 2019
 

Mereo BioPharma Group plc

 

 ("Mereo" or the "Company")

 

Notification of PDMR Dealing

 

London, August 15, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on August 13, 2019, Charles Sermon, General Counsel, purchased 590 American Depositary Shares (ADSs) at a price of USD3.09 per ADS. On August 14, 2019, Charles purchased 754 ADSs at a price of USD3.11 per ADS.

 

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Charles Sermon

 

2

Reason for the notification

a)

Position/status

General Counsel

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

 

b)

Nature of the transaction

PURCHASE OF ADS

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD 3.09

590

 

 

d)

Aggregated information: volume, Price

Aggregated volume: 590

Aggregated price: USD3.087

e)

Date of the transaction

2019-08-13

f)

Place of the transaction

XNMS

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Charles Sermon

 

2

Reason for the notification

a)

Position/status

General Counsel

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

 

b)

Nature of the transaction

PURCHASE of ADS

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD3.11

754

 

 

d)

Aggregated information: volume, Price

Aggregated volume: 754

Aggregated price: GBP3.105

e)

Date of the transaction

2019-08-14

f)

Place of the transaction

XNMS

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBUGDIIUBBGCU

Related Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Back to RNS